soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 results Oral Semaglutide in High-Risk Type 2 Diabetes: Cardiovascular Benefit Confirmed in the SOUL Trial Clinical Effectiveness and Safety of – Oral Semaglutide and Cardiovascular Outcomes

Activation of cAMP signaling inhibits DNA damageinduced apoptosis in BCP-ALL cells through abrogation of p53 accumulation

A meta-analysis of three studies including 1,119 participants found that individuals with PAM variants responded less well to GLP-1 receptor agonists and were less likely to lower their HbA1c, a measure of long-term blood sugar

Goto H, Nomiyama T, Mita T, Yasunari E, Azuma K, Komiya K, et al

Injectable peptides can cause minor injection site reactions, including swelling, tenderness, or bruising, while systemic effects are rare

GHK-Cu 20 mg/ml Sublingual Drop: Systemic delivery for comprehensive support

Meaning, their generic versions are not yet available